{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:21:07Z","timestamp":1792614067477,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,10,8]],"date-time":"2017-10-08T00:00:00Z","timestamp":1507420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kaposi sarcoma (KS) is the most common paediatric cancer in human immunodeficiency virus (HIV) endemic countries of sub\u2010Saharan Africa, but there is little research on management and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children with KS at Queen Elizabeth Central Hospital, Blantyre, Malawi treated between August 2012 and March 2015 with six courses of vincristine, bleomycin and etoposide combination chemotherapy, including antiretroviral therapy (ART) if HIV infected, were studied and outcomes compared with previously reported results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Fifty\u2010six children were included; 38 (68%) were male; and 48 (86%) were HIV positive, of whom 36 (77%) were on ART at diagnosis. Median age at diagnosis was 8 years (interquartile range [IQR] 3\u201312) and median follow\u2010up was 16.9 months (IQR 3.4\u201336.4). Quality of life improved in 45 (80%) children; the median Lansky Score increased from 80% pre\u2010treatment to 100% post\u2010treatment. Eighteen (32%) children had complete response to treatment. At 12 months, overall survival was 71% (95% confidence interval [CI] 56\u201382) and event\u2010free survival (event\u00a0=\u00a0death, loss to follow\u2010up or relapse) was 50% (95% CI 36\u201363). At 1 year, the risk of loss to follow\u2010up was 13.4%. In a previous, same\u2010site, randomized controlled study of vincristine monotherapy, vincristine and bleomycin, or oral etoposide, oral etoposide monotherapy had the best outcome with survival at 12 month of 66% (95% CI 46\u201380) and event\u2010free survival of 52% (95% CI 33\u201368); however, loss to follow\u2010up was not reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall survival, event\u2010free survival and quality of life appear to have improved with this three\u2010agent combination chemotherapy; however larger, randomized studies are needed to determine optimal management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.26841","type":"journal-article","created":{"date-parts":[[2017,10,8]],"date-time":"2017-10-08T07:52:41Z","timestamp":1507449161000},"source":"Crossref","is-referenced-by-count":12,"title":["Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9943-4495","authenticated-orcid":false,"given":"Marita","family":"Macken","sequence":"first","affiliation":[{"name":"Department of Paediatric Oncology Birmingham Children's Hospital  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Dale","sequence":"additional","affiliation":[{"name":"Sheffield Children's Hospital  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Moyo","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Central Hospital College of Medicine  Blantyre Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Chakmata","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Central Hospital College of Medicine  Blantyre Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Depani","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4309-4994","authenticated-orcid":false,"given":"Trijn","family":"Israels","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalida","family":"Niyrenda","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Central Hospital College of Medicine  Blantyre Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-4329","authenticated-orcid":false,"given":"Simon","family":"Bailey","sequence":"additional","affiliation":[{"name":"Sir James Spence Institute of Child Health Royal Victoria Infirmary  Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chagaluka","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Central Hospital College of Medicine  Blantyre Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Molyneux","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Central Hospital College of Medicine  Blantyre Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016209789973619"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318251aedd"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.6757"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-1-114"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70036-0"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.777347"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3085"},{"key":"e_1_2_8_9_1","first-page":"S158","article-title":"Kaposi sarcoma in HIV\u2010infected children: a novel clinical staging classification determines risk stratification","volume":"61","author":"El\u2010Mallawany N","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24408"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24516"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22369"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22903"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318228fb04"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20606"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.02.019"},{"key":"e_1_2_8_17_1","unstructured":"Clinical Management of HIV in Children and Adults.Malawi integrated guidelines for providing HIV services.2014.http:\/\/www.emtct-iatt.org\/wp-content\/uploads\/2015\/09\/Malawi-HIV-Guidelines-2014.pdf."},{"key":"e_1_2_8_18_1","unstructured":"HIV Unit Ministry of Health Malawi.Antiretroviral therapy.http:\/\/www.hivunitmohmw.org\/Main\/Antiretroviral\/Therapy."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J"},{"issue":"1","key":"e_1_2_8_20_1","first-page":"CD009826","article-title":"Treatment of Kaposi sarcoma in children with HIV\u20101 infection","author":"Anglemyer A","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"e_1_2_8_21_1","first-page":"CD003256","article-title":"Treatment of severe or progressive Kaposi's sarcoma in HIV\u2010infected adults","volume":"8","author":"Gbabe OF","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80081-V"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1996.tb02990.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920050-00002"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.26841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T11:26:21Z","timestamp":1695986781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.26841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/pbc.26841"],"URL":"https:\/\/doi.org\/10.1002\/pbc.26841","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,8]]},"article-number":"e26841"}}